A 76-year-old man presented with leukostasis syndrome, including oculodynia, blurred vision, and visual field defects, due to mantle cell lymphoma, prolymphocytoid variant, with marked leukocytosis, 1227 Â 10 9 /l. He had splenomegaly but no lymphadenopathy or hepatomegaly. The tumor cells were CD5 þ , CD19 þ , CD20 þ , FMC-7 þ , and kappa light chain restricted. Immunohistochemistry showed expression of p53 and of cyclin D1. Fluorescent in situ hybridization demonstrated t(11;14) with translocation between CYCLIN D1 and the immunoglobulin heavy-chain genes. The patient received leukapheresis and aggressive chemotherapy, but the leukocyte count remained above 100 Â 10 9 /l. The patient's condition rapidly deteriorated with lymphomatous infiltration of his lungs and soft tissues, and he expired 6 months after diagnosis. While it is known that mantle cell lymphoma may have a leukemic phase, the degree of leukocytosis in this case exceeds that previously reported in the literature and resulted in a clinical syndrome of leukostasis.
The recent World Health Organization (WHO) classification defines mantle cell lymphoma as a distinct entity characterized by a unique immunophenotype (CD5 þ , CD19 þ , CD20 þ , FMC-7 þ , bcl-2 þ , cyclin D1 þ ) and molecular translocation between the CYCLIN D1 gene on chromosome 11 and the immunoglobulin heavy-chain gene on chromosome 14, t(11;14)(q13;q32). 1 While most cases are composed of small-to medium-sized lymphoid cells resembling centrocytes, the WHO recognizes four morphologic variants, including two blastoid forms (classic and pleomorphic) and variants resembling small lymphocytic or marginal zone B-cell lymphoma. The medical literature has reports of another variant termed prolymphocytoid or nucleolated. [2] [3] [4] [5] The identification of mantle cell lymphoma is important because of its aggressive clinical course. It is incurable with standard treatment regimens and has a median survival of only 3-5 years. [6] [7] [8] Reports of mantle cell leukemia with prolymphocytoid or nucleolated morphology, as seen in the current case, are rare. [2] [3] [4] [5] We are aware of only one prior report describing mantle cell lymphoma with a leukocyte count over 300 Â 10 9 /l (689 Â 10 9 /l). 4 Here, we describe a case of mantle cell lymphoma, prolymphocytoid variant, with marked leukocytosis of 1227 Â 10 9 /l and with a leukostasis syndrome.
Case presentation
A 76-year-old man presented to his ophthalmologist with a 4-month history of oculodynia, blurred vision, and weight loss of 4.5 kg. He had no fever, chills, or diaphoresis. A complete blood count revealed leukocytosis of 1227 Â 10 9 /l with 98% lymphocytes (Table 1) . His past medical history and family history were unremarkable. Physical examination revealed a visual field defect peripherally. His lungs were clear to auscultation. He had splenomegaly but no adenopathy, hepatomegaly, or skin lesions. Additional blood studies showed a positive direct Coombs, but haptoglobin and bilirubin were normal.
Computerized tomography scan of the chest, abdomen, and pelvis revealed mild splenomegaly without focal lesions. There were interstitial changes in the lung bases along with a left pleural effusion. There was no lymphadenopathy. A magnetic resonance imaging study of the brain was unremarkable.
A bone marrow biopsy was performed. The bone marrow morphology, flow cytometry, immunohistochemistry, and cytogenetic FISH analysis were consistent with mantle cell lymphoma, prolymphocytoid variant.
Owing to the leukostasis syndrome, the patient was treated with daily leukapheresis for 1 week. The leukocyte count dropped to 670 Â 10 9 /l, resulting in symptomatic relief. The leukapheresis was followed by chemotherapy with hyperCVAD (cyclophosphamide, doxorubicin, vincristine and dexamethasone) alternating with methotrexate and cytosine arabinoside. After two cycles of chemotherapy, the leukocyte count dropped to 415 Â 10 9 /l, and a postchemotherapy bone marrow biopsy showed persistent extensive involvement by mantle cell lymphoma. The patient's leukocyte count never dropped below 100 Â 10 9 /l ( Figure 1 ).
The patient's clinical course was complicated by a fever that subsided with antibiotics, and deep venous thrombosis of the left upper arm that required anticoagulation therapy. Supportive therapy, including hydroxyurea and three additional treatments of leukapheresis, was provided over the following months, but this was not effective in further reducing the leukocyte count. The patient developed a deep thigh mass and a symptomatic pleural effusion that showed involvement by lymphoma on fine-needle aspiration and thoracentesis, respectively. He died 6 months after diagnosis. No autopsy was performed.
Materials and methods

Morphology
The peripheral blood was stained with WrightGiemsa and bone marrow aspirate smears were stained with Jenner-Giemsa. The bone marrow aspirate clot and needle core biopsy were fixed in B5, embedded in paraffin, and stained with hematoxylin and eosin.
Flow Cytometry
Three-color flow cytometry was performed on the peripheral blood and bone marrow aspirate using a FACScan (Becton, Dickinson, and Company, San Jose, CA, USA). Briefly, leukocytes were isolated from EDTA anticoagulated peripheral blood or marrow by centrifugation with 0.1% bovine serum albumin in phosphate-buffered saline and were incubated with antibodies directed to the following antigens: CD2, CD3, CD4, CD5, CD7, CD8, CD10, CD11c, CD16, CD19, CD20, CD23, CD34, CD38, CD45, CD56, CD64, FMC-7, and kappa and lambda immunoglobulin light chains. Listmode files were analyzed with WinList (Verity Software House, Topsham, ME, USA).
Immunohistochemistry
Immunohistochemical stains were performed on the aspirate clot and bone marrow core biopsy using an Autostainer (DakoCytomation, Inc., Carpinteria, CA, USA). Sections were deparaffinized in xylene and alcohol. Antigen retrieval for CD5, CD10, CD20, CD23, CD45, bcl-2, p53 (DO-7) was accomplished by steaming the paraffin sections in EDTA buffer for 30 min using a commercial vegetable steamer. Antigen retrieval for cyclin D1 (DCS-6) was performed by steaming sections in citrate buffer for 25 min. Detection was with the avidin-biotin peroxidase complex. 
Pathology
The peripheral blood smear showed marked leukocytosis of small-to medium-sized mature lymphocytes with coarse chromatin and with slightly irregular nuclear contours ( Figure 2 ). Many of the tumor cells had one or more prominent nucleoli. There were occasional cytoplasmic blebs and rare free cytoplasmic fragments. Lymphocytes with similar morphology accounted for 86% of nucleated cells in the bone marrow aspirate smears. The bone marrow biopsy was markedly hypercellular (495%) due to a diffuse lymphoid infiltrate.
Immunophenotyping by flow cytometry revealed a discrete lymphoid population (bright CD45 and low side scatter) that expressed CD5, CD19, moderate intensity CD20, FMC-7, and moderate intensity monotypic kappa light chain. Immunohistochemistry on paraffin-embedded tissues showed strong staining for CD20, p53 (480% of cells) and bcl-2. Staining was positive focally for cyclin D1. CD5, CD23, and CD45RO were negative by immunohistochemistry. FISH on the marrow aspirate identified the t(11;14)(q13;q32) between the immunoglobulin heavy-chain gene and CYCLIN D1 gene in 197 cells out of 200 (Figure 2 ).
Discussion
We report a case of mantle cell lymphoma, prolymphocytoid variant, presenting with marked leukocytosis and with a leukostasis syndrome, including oculodynia, blurred vision, and visual field defects. To our knowledge, the absolute lymphocyte count of 1227 Â 10 9 /l is the highest level reported in the medical literature for mantle cell lymphoma. The diagnosis was confirmed by morphology and by ancillary studies. Immunophenotyping by flow cytometry was consistent with mantle cell lymphoma. Immunohistochemistry showed expression of cyclin D1. FISH demonstrated the t(11;14) translocation between the immunoglobulin heavy-chain gene and CYCLIN D1 gene.
Prior reports have described mantle cell lymphoma involving the peripheral blood, although the amount of involvement varies in the medical literature. Cohen et al 9 identified leukemic lymphoma cells in 77% (27/35) of patients with mantle cell lymphoma, but most of these cases did not have an absolute lymphocytosis at diagnosis. Other studies indicate that overt involvement of peripheral blood is less common (10-27%). 1, 10, 11 The patient reported here had marked leukocytosis causing leukostasis syndrome, which is a rare occurrence in mantle cell lymphoma.
Most patients with mantle cell lymphoma present with lymphadenopathy, 1 but recent studies have noted that some patients present with marked leukocytosis, marrow involvement, and splenomegaly but no lymphadenopathy, similar to the current case. The latter cases were sometimes misdiagnosed as prolymphocytic leukemia in the older medical literature. Mantle cell lymphoma and prolymphocytic leukemia may have similarities in clinical presentations, microscopic features, and flow cytometric immunophenotypes. Mantle cell lymphoma is distinguished by increased cyclin D1 resulting from the t (11;14) translocation between the immunoglobulin heavy-chain and CYCLIN D1 genes. Prolymphocytic leukemia lacks these features.
The current case was classified as mantle cell lymphoma, prolymphocytoid variant. There have been four prior reports of prolymphocytoid or nucleolated mantle cell lymphoma. [2] [3] [4] [5] The previously reported cases had the t(11;14) by either conventional cytogenetics or FISH. Mantle cell lymphoma had a characteristic immunophenotype: CD5 þ , CD19 þ , and CD20 þ , and usually negative for CD23. Cyclin D1 was increased in 97% (28/29), and FMC-7 was positive in 89% (24/27). One study reported a worse overall survival for a large/blastoid morphologic variant compared to a small-cell type. 4 Clinical follow-up in all four studies ranged from 1 to 126 months with three patients alive at the time of publication. The current patient died 6 months after diagnosis.
The current patient's high tumor burden is a contributing factor to the aggressiveness of this leukemic presentation. Leukostasis syndromes may be associated with headache, confusion, tinnitus, papilledema, ataxia, obtundation, dyspnea, hypoxemia, metabolic abnormalities, coagulopathy, and tumor lysis syndrome. 12 The current patient presented with leukocytosis of 1227 Â 10 9 /l, with oculodynia, blurred vision, and visual field defects. The patient's symptoms improved with leukapheresis. The combination of leukapheresis and highdose chemotherapy reduced the leukocyte count but not below 100 Â 10 9 /l. The poor outcome in this case may be linked not only to the aggressive morphologic subtype of mantle cell lymphoma and to the leukocytosis but also to abnormal p53. The marrow biopsy had increased p53 protein. Wild-type p53 acts as a tumor suppressor gene that can induce growth arrest and/or apoptosis when DNA mutations occur in the cell. However, p53 mutations can inhibit this important function, allowing the cell to undergo mitosis in the presence of genetic defects. [13] [14] [15] Although p53 mutations are rare in small B-cell lymphomas, up to half of high-grade B-cell lymphomas have been shown to overproduce p53 protein, presumably due to p53 gene mutations resulting in abnormal stabilization of the protein. 16 In addition, p53 mutations have been found in high grade transformation of low-grade lymphomas. [17] [18] [19] Some studies have found that p53 mutations and/or overproduction in mantle cell lymphoma are associated with aggressive variants, including large cell or blastic types. [20] [21] [22] Wong et al 5 found overexpression of p53 in one of four nucleolated mantle cell lymphomas. These findings support the hypothesis that mutations of p53 or other genes involved in cell cycle regulation are associated with transformation of typical mantle cell lymphoma to an aggressive type. 23 In conclusion, we present a case of mantle cell lymphoma with aggressive features: prolymphocytoid morphology, p53 overproduction, marked leukocytosis, and leukostasis syndrome. It is likely that these biological features played an important role in the rapid clinical course. This case underscores the need for new therapeutic approaches for treating patients with mantle cell lymphoma.
